Table 1.
Demographic and clinical data (mean±standard deviation).
| Subjects | Number per group | Gendera | Age (years)b | PMI (hours)c | Duration of illness (years) | NTR (chlorpromazine equivalents) |
|---|---|---|---|---|---|---|
| Mean±SD | Mean±SD | Mean±SD | Mean±SD | |||
| Controls | 20 | 12M, 8F | 58.3±12.6 | 6.1±1.0 | ||
| Schizophrenia | 21 | 11 M, 10F | 56.3±16.8 | 6.2±1.0 | 28.2±13.0 | 406.5±303.6 |
| SPNS | 9 | 5M, 4F | 56.2±17.8 | 5.6±0.7 | 29.3±15.7 | 457.0±378.6 |
| SPPS | 12 | 6M, 6F | 56.4±16.8 | 6.6±1.1 | 27.42±13.0 | 367.2±253.1 |
PMI, postmortem interval. SPPS, the subgroup with predominantly positive symptoms; SPNS, the subgroup with predominantly negative symptoms; NTR, neuroleptic treatment. Controls vs. SCZ: aChi-square test (p = 0.43), bANOVA (p = 0.92), cANOVA (p = 0.24).